8-K/A: Myriad Genetics Q3 2025: Revenue Flat Ex-Headwinds, Guidance Reaffirmed

Myriad Genetics reported third quarter 2025 financial results, with revenue of $205.7 million, and reaffirmed its full-year 2025 financial guidance.

Summary

• Third quarter 2025 revenue was $205.7 million, a 4% decrease year-over-year, but flat when excluding previously discussed headwinds of $8.1 million.
• Hereditary cancer testing revenue grew 3% year-over-year, with volume increasing 11% year-over-year.
• Gross margin for the quarter was 69.9%.
• GAAP net loss was $27.4 million, or $0.29 per share, while adjusted EPS was $0.00.
• Adjusted EBITDA for the third quarter was $10.3 million.
• Total test volumes increased 3% year-over-year to 386,000.
• Cash flow provided by operations was $21.1 million, with cash and cash equivalents totaling $145.4 million at quarter-end.
• The company entered a strategic collaboration with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic (CDx) testing solution.
• Full-year 2025 financial guidance for revenue, gross margin, adjusted operating expenses, adjusted EBITDA, and adjusted EPS was reiterated.

Sentiment

Score: 6

Explanation: The company reaffirmed its full-year guidance and showed stable revenue performance excluding specific headwinds, indicating execution in line with expectations. Strong growth in hereditary cancer and strategic partnerships are positive. However, overall revenue declined, and GAAP net loss persists, with significant impairment charges for the nine-month period. The correction to the beginning cash balance is a clerical error but highlights attention to detail.

Positives

• Stable year-over-year revenue performance when excluding previously noted headwinds of $8.1 million, consistent with management expectations.
• MyRisk hereditary cancer test volume grew 13% year-over-year, contributing to a 3% increase in hereditary cancer testing revenue.
• Gross margin of 69.9% is stated as being among the best in the industry.
• Achieved positive adjusted EBITDA of $10.3 million for the quarter.
• Oncology hereditary cancer testing revenue increased 2% year-over-year, with volume up 9%.
• Prolaris testing revenue grew 3% year-over-year.
• Women's Health hereditary cancer testing revenue and volume for the unaffected population increased 4% and 11% year-over-year, respectively, driven by EMR solutions and breast cancer risk assessment programs.
• Prenatal testing revenue grew 2% year-over-year, reflecting ongoing expansion of payer coverage for Foresight Expanded Carrier Screen.
• GeneSight test volume grew 8% year-over-year, showing ongoing improvement in growth rates.
• Strategic collaboration with SOPHiA GENETICS to develop an innovative global liquid biopsy companion diagnostic (CDx) testing solution.
• Progress towards the commercial launch of an AI-enabled prostate cancer test in partnership with PATHOMIQ in the first half of 2026.
• Precise MRD test demonstrated high performance in detecting ctDNA levels in patients with very low tumor burden (94% below 100 ppm) in a study published in The Lancet Oncology.
• Added F8 and FXN genes to its Foresight Universal Plus Panel, now including all conditions recommended by the American College of Medical Genetics and Genomics for prenatal screening.

Negatives

• Total revenue decreased by 4% year-over-year to $205.7 million.
• Reported a GAAP net loss of $27.4 million, or $0.29 per share.
• Adjusted EPS was $0.00, down from $0.06 in the prior year quarter.
• Tumor profiling revenue decreased 7% year-over-year, primarily due to the divestiture of the European EndoPredict business in August 2024.
• Prenatal volume decreased 3% year-over-year, largely driven by lower demand for SneakPeek.
• Pharmacogenomics revenue decreased 19% year-over-year to $38.7 million, reflecting the impact of UnitedHealthcare's discontinuation of coverage for multi-gene panel pharmacogenetic testing, including GeneSight.
• Operating loss for the quarter was $23.3 million.
• Goodwill and long-lived asset impairment charges of $2.2 million were recorded in the third quarter of 2025, and $316.7 million for the nine months ended September 30, 2025.

Risks

• Sales and profit margins of existing tests may decline.
• Inability to operate the business on a profitable basis.
• Risks related to the company's ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable.
• Risks related to recent changes in the company's senior management team and the successful implementation of the company's strategic plan.
• Risks related to changes in governmental or private insurers' coverage and reimbursement levels for the company's tests, or the company's ability to obtain reimbursement for new tests at comparable levels, including with respect to UNH's coverage decisions for GeneSight.
• Increased competition and the development of new competing tests.
• Inability to develop or achieve commercial success for additional tests in a timely manner, or at all.
• Inability to secure additional financing to fund the business, if needed, in a timely manner or on favorable terms.
• Failure to successfully develop new markets or channels for its tests.
• Termination or inability to maintain licenses to the technology underlying the company's tests on satisfactory terms.
• Delays or other problems with operating the company's laboratory testing facilities.
• Public concern over genetic testing in general or the company's tests in particular.
• Risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems.
• Inability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms.
• Failure to successfully integrate and derive benefits from any technologies or businesses that are licensed, acquired, or developed.
• Inaccurate projections or estimates about the potential market opportunity for current and future products.
• Inability to protect proprietary technologies or infringement by third parties.
• Risks of patent-infringement claims or challenges to the validity of the company's patents.
• Changes in intellectual property laws covering the company's tests, or patents or enforcement, in the United States and foreign countries.
• Security breaches, loss of data, and other disruptions, including from cyberattacks and other cybersecurity incidents.
• Risks of new, changing, and competitive technologies in the United States and internationally, and the company's ability to keep pace with rapid technology changes or properly leverage new technologies.
• Inability to comply with financial or operating covenants under credit or lending agreements.
• Inability to maintain effective disclosure controls and procedures and internal control over financial reporting.
• Current and future investigations, claims, or lawsuits, including derivative claims, product or professional liability claims, and risks related to insurance coverage limits.

Future Outlook

Myriad Genetics reiterated its full-year 2025 financial guidance, expecting revenue between $818 million and $828 million, gross margin between 69.5% and 70.0%, adjusted operating expenses between $562 million and $568 million, adjusted EBITDA between $27 million and $33 million, and adjusted EPS between $(0.02) and $0.02. The company plans to commercially launch its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, in the first half of 2026. The strategic collaboration with SOPHiA GENETICS is expected to leverage Myriad's capabilities to support clinical trials, companion diagnostic test development, and FDA registration, initially focusing on liquid biopsy applications.

Management Comments

• "I am pleased with our solid results for the quarter, including stable year-over-year revenue performance excluding previously noted headwinds, and 13% year-over-year volume growth for our MyRisk hereditary cancer test." Sam Raha, President and CEO.
• "Our disciplined execution also enabled our gross margin to be among the best in the industry and again yielded positive adjusted EBITDA." Sam Raha, President and CEO.
• "We are executing on our updated strategy to accelerate profitable growth by focusing on the Cancer Care Continuum, including recently entering into a collaboration with SOPHiA GENETICS to provide Pharma customers with CDx development services using a leading liquid biopsy therapy selection assay." Sam Raha, President and CEO.
• "We also made changes to our organizational structure and capital deployment, and expect these actions to support us in improving customer experience, gaining market share, and reducing operating expenses as a percentage of revenue going forward." Sam Raha, President and CEO.

Industry Context

Myriad Genetics operates in the dynamic molecular diagnostic testing and precision medicine industry, with a focus on oncology, women's health, and pharmacogenomics. The strategic collaboration with SOPHiA GENETICS for liquid biopsy companion diagnostics aligns with the broader industry trend towards personalized medicine and advanced diagnostic solutions in cancer care. The development of an AI-enabled prostate cancer test also reflects the increasing integration of artificial intelligence to enhance diagnostic accuracy and efficiency. Challenges in pharmacogenomics revenue due to payer coverage changes, such as UnitedHealthcare's discontinuation for GeneSight, highlight the ongoing complexities and reimbursement hurdles within the diagnostic testing market.

Comparison to Industry Standards

• Myriad's reported gross margin of 69.9% is stated as being 'among the best in the industry,' suggesting strong operational efficiency compared to other molecular diagnostic companies.
• The strategic collaboration with SOPHiA GENETICS for liquid biopsy companion diagnostics positions Myriad in a competitive segment, similar to efforts by companies like Guardant Health (Guardant360 CDx) and Foundation Medicine (FoundationOne Liquid CDx) in developing advanced liquid biopsy solutions for therapy selection.
• The planned commercial launch of an AI-enabled prostate cancer test with PATHOMIQ is comparable to initiatives by other diagnostic firms leveraging AI, such as Paige.AI in digital pathology or Tempus in oncology, to improve diagnostic accuracy and patient stratification.
• The meta-analysis supporting GeneSight's efficacy in improving response and remission rates for MDD patients reinforces the clinical utility of pharmacogenomic testing, a field where companies like Genomind and other specialized labs also operate, aiming to personalize mental health treatment.

Stakeholder Impact

• Shareholders: Reaffirmed guidance provides some stability, but persistent GAAP losses and the correction to the beginning cash balance may warrant scrutiny. Strategic collaborations and product pipeline offer potential for future growth.
• Customers: The introduction of new tests (AI prostate cancer, CDx) and expanded panels (Foresight) aims to enhance diagnostic options and improve customer experience.
• Employees: Mention of changes to organizational structure by management could imply restructuring or reallocation of resources, potentially impacting employees.
• Payer/Insurers: Ongoing expansion of payer coverage for Foresight is positive, but the discontinuation of GeneSight coverage by UnitedHealthcare highlights continued challenges in reimbursement.
• Partners (SOPHiA GENETICS, PATHOMIQ): New collaborations indicate active engagement and potential for joint development and market expansion in key strategic areas.

Next Steps

• Commercially launch the first AI-enabled prostate cancer test, in partnership with PATHOMIQ, in the first half of 2026.
• Continue executing on the updated strategy to accelerate profitable growth by focusing on the Cancer Care Continuum.
• Leverage the SOPHiA GENETICS partnership to support clinical trials, companion diagnostic test development, and FDA registration, initially focusing on liquid biopsy.

Key Dates

Recommendation

The company is executing on a strategic plan with some positive operational highlights, including growth in hereditary cancer testing and new collaborations in liquid biopsy and AI diagnostics. The reaffirmation of full-year guidance suggests performance is largely in line with expectations. However, the overall revenue decline, persistent GAAP losses, and significant headwinds in the pharmacogenomics segment (GeneSight) present ongoing challenges. The stock is likely to remain range-bound as investors weigh strategic progress against profitability challenges and market headwinds, warranting a 'hold' position for now.

Keywords

Myriad Genetics, MYGN, molecular diagnostics, precision medicine, genetic testing, hereditary cancer, tumor profiling, prenatal testing, pharmacogenomics, GeneSight, MyRisk, Foresight, Prolaris, SOPHiA GENETICS, liquid biopsy, companion diagnostics, CDx, AI, prostate cancer, Q3 2025 earnings, financial results